Seyed Jafari, S. Morteza; Feldmeyer, Laurence; Hunger, Robert E. (2020). Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab. Frontiers in oncology, 10, p. 573527. Frontiers Research Foundation 10.3389/fonc.2020.573527
|
Text
fonc-10-573527.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (466kB) | Preview |
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Jafari, Morteza, Feldmeyer, Laurence, Hunger, Robert |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2234-943X |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
10 Dec 2020 13:48 |
Last Modified: |
02 Mar 2023 23:34 |
Publisher DOI: |
10.3389/fonc.2020.573527 |
PubMed ID: |
33117707 |
Uncontrolled Keywords: |
checkpoint inhibitors extragenital lichen sclerosus et atrophicus ipilimumab malignant melanoma metastatic nivolumab |
BORIS DOI: |
10.7892/boris.148365 |
URI: |
https://boris.unibe.ch/id/eprint/148365 |
Actions (login required)
 |
Edit item |